134 articles with Blueprint Medicines
Blueprint Medicines Corporation and privately held CStone Pharmaceuticals have entered into a partnership to develop and commercialize avapritinib, BLU-554 and BLU-667 in mainland China, Hong Kong, Macau and Taiwan, either as monotherapies or combination therapies.
Blueprint Medicines Corporation announced its participation in several upcoming investor conferences.
Blueprint Medicines Corporation reported financial results and provided a business update for the quarter ended March 31, 2018.
Blueprint Medicines Corporation announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, May 2, 2018 to report its first quarter 2018 financial results and provide a corporate update.
Blueprint Medicines Corporation, a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2017.
Blueprint Medicines to Report Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 21, 2018
The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.
Blueprint Medicines today announced the pricing of an underwritten public offering of 3,703,704 shares of its common stock at a public offering price of $81.00 per share, before underwriting discounts and commissions.
Blueprint Medicines today announced that it has commenced an underwritten public offering of $275,000,000 in shares of its common stock.
12/12/2017A look at some of the exciting data clinicians and investors got to feast on from ASH.
Blueprint Medicines Announces New Data From Ongoing Phase I Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity
The new data from the dose escalation portion of the Phase I trial showed strong clinical activity regardless of advanced SM subtype, prior treatment with midostaurin or the presence of additional mutations.
Blueprint Medicines Announces New Data From Ongoing Phase I Clinical Trial of BLU-285 in Patients With Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity Across Spectrum of KIT and Pdgfrα Genotypes
The data confirm and build upon data previously presented for BLU-285 in patients with advanced GIST, demonstrating robust clinical activity and a favorable safety profile.
Blueprint Announces Appointment Of Christopher Murray, Ph.D. As Senior Vice President, Technical Operations
Alexion Redefines R&D Strategy, Discontinues Programs and Kills Deals With Moderna, Blueprint and Arbutus Biopharma